Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Trap-Eye vs Visudyne in neovascular AMD (China)
CTR20131739Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in exudative macular degeneration, sponsored by Bayer. Started Apr 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20131739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131739.